WHITE PLAINS, N.Y., Feb. 4, 2026 — Manor Park Ventures, a family-backed real estate investment and development firm, today announced the opening of its new headquarters at Switch2 Ten, the newly redeveloped former NYNEX building located at 10 County Center Road in White Plains, New York.
The relocation marks an important milestone for the firm as it continues to expand its development platform and strengthen its presence throughout the Northeast. The new headquarters provides Manor Park Ventures with a modern, flexible environment designed to support collaboration, strategic growth, and long-term operations.
“Our move to Switch2 Ten reflects the evolution of Manor Park Ventures and the direction we are heading,” said Marc Weil, President of Manor Park Ventures. “As our portfolio and partnerships continue to grow, it is important to establish a headquarters that matches the scale, professionalism, and ambition of our firm.”
The firm’s new office features a thoughtfully designed layout with dedicated collaboration areas. Its central White Plains location offers convenient access to Westchester County Airport, regional rail service, key institutional partners, and major transportation corridors.
“This new space allows us to better support our partners, investors, advisors, and development teams while continuing to build a platform designed for durability and long-term growth,” added Weil.
Manor Park Ventures is actively advancing a pipeline of multifamily and mixed-use developments across high-growth markets in the Northeast and Southeast United States, including Knoxville, Tennessee, and Huntsville, Alabama. Supported by family capital and a disciplined, principal-driven investment approach, the firm also evaluates select investments beyond real estate, including technology and specialty operating businesses.
About Manor Park Ventures Manor Park Ventures is a family-backed real estate investment and development firm focused on the acquisition, development, and operation of strategic real estate assets. Concentrating on opportunistic multifamily development projects throughout the Northeast and Southeast United States, the firm partners with developers and family offices that share a long-term investment philosophy and commitment to value creation.
Led by Santé Ventures, the funding will enable beHuman to expand its network of health insurance partners and end customers nationally
MIAMI, Feb. 4, 2026 — beHuman, a physician-led preventive care platform focused on improving early cancer detection for underserved populations, today announced it has raised a $4 million seed round led by Santé Ventures, with participation from DHVP.io. The funding will support beHuman’s expansion beyond its current footprint in the north and southeast, accelerating its mission to make early cancer screening more accessible to patients nationwide.
While early cancer detection has become an increasingly active area of innovation within healthcare, many existing solutions primarily serve affluent, highly engaged consumers. beHuman offers a vertically-integrated solution that is designed to reach a different, and often far larger, population: insured patients who rarely or never receive recommended screenings due to geographic barriers, limited access to care, administrative complexity, or longstanding mistrust of the healthcare system.
“Early detection dramatically improves outcomes, yet millions of insured Americans are still diagnosed too late simply because the system never reaches them,” said Steve Yaskin, Founder and CEO of beHuman. “beHuman was built to meet patients where they are, especially those in rural and underserved communities, by removing friction, restoring trust, and making prevention simple, accessible, and life-saving.”
beHuman integrates virtual clinical care, advanced diagnostic testing, and longitudinal health data access to proactively identify cancer risk and guide patients through appropriate screening pathways. Its agentic AI platform automates key administrative workflows such as eligibility verification, scheduling, chart review, and follow-up, which reduces the burden on clinicians while preserving rigorous, physician-led care.
Importantly, beHuman’s model directly addresses patient concerns around data privacy and misuse, which are especially prevalent in underserved communities. The platform is designed with strict data governance, transparency, and clinical oversight to ensure patient information is used solely to support care.
Early results show that beHuman’s cancer detection rates exceed national averages. By engaging patients earlier in the disease timeline, beHuman is able to uncover risk that would otherwise go undetected until far later stages. Furthermore, the service is covered by most major insurance plans, eliminating cost as a barrier and enabling patients to participate in preventive care without a significant out-of-pocket expense.
Santé Ventures brings deep experience backing healthcare companies that modernize care delivery and improve outcomes at scale. “beHuman is addressing one of healthcare’s most persistent gaps, late cancer detection among populations the system consistently misses,” said Kevin Lalande, Founding Managing Director and Chief Investment Officer at Santé Ventures. “The team’s combination of physician leadership, thoughtful AI automation, and focus on trust and access positions them to deliver meaningful impact nationwide.”
With the new funding, beHuman will:
Expand into additional states
Deepen partnerships with leading diagnostic laboratories
Advance its agentic AI platform to further streamline preventive care workflows
Scale its physician-led virtual care teams to serve more patients efficiently
As beHuman grows, the company remains focused on its core principle: prevention works best when it is equitable, trusted, and easy to access. To learn more about beHuman, please visit www.behuman.health.
About beHuman beHuman is a physician-led preventive care platform using AI to make early cancer detection accessible at scale. By combining virtual care, advanced diagnostics, and automated workflows, beHuman helps underserved and under-screened patients identify cancer risk earlier and navigate screening with confidence. The platform is covered by most insurance plans and currently operates across multiple U.S. states.
About Santé Ventures Founded in 2006, Santé Ventures is a specialized healthcare and life sciences investment firm with over $1 billion in capital under management. The firm invests in early-stage companies developing innovative new medical technologies, biotechnologies, and digitally enabled healthcare services. Recent Santé successes include Laminar (Johnson & Johnson), Farapulse (Boston Scientific), Healthcare Highways – CerpassRx (Nomi Health), Claret Medical (Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), Molecular Templates (MTEM), AbVitro (Bristol Myers Squibb), and Explorys (IBM Corp). Santé invests nationally and has offices in Austin, TX and Boston, MA. For more information, please visit www.sante.com.
$52M equity adds to previously announced $165M Series A
New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures, and Alderline Group
SPRING HOUSE, Pa., Feb. 4, 2026 — Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the closing of a $52 million Series A extension.
New investor Andreessen Horowitz (a16z) joined Third Arc Bio’s existing world-class investor syndicate to further validate the company’s approach to deliver transformational therapies for patients. As part of the financing, a16z General Partner, Jorge Conde, joins Third Arc Bio’s Board of Directors. Proceeds from the financing will enable Third Arc Bio to accelerate its I&I portfolio and deliver additional oncology programs into the clinic.
“Third Arc represents a shift toward more precise immune modulation—moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease,” said Jorge Conde, General Partner at a16z. “The company’s platforms, combined with a team that has repeatedly translated complex immunology into approved medicines, reflect a rigorous, patient-driven approach to building biologics that can improve both efficacy and safety across oncology and immune-mediated disease.”
Since its launch in 2022 with seed financing from Omega Funds, Third Arc Bio has assembled a highly experienced team with a proven track record of drug discovery and development, alongside an innovative platform and a pipeline of multispecific antibodies. The company’s lead asset, ARC101, is a bispecific T cell engager targeting CLDN6 currently in Phase 1 dose escalation in patients with advanced solid tumors.
“This financing allows us to maintain momentum across our expanding oncology portfolio while rapidly advancing our next-generation I&I assets into first-in-human studies,” said Peter F. Lebowitz, MD, PhD, Chief Executive Officer of Third Arc Bio. “By parallel-tracking programs, we can more efficiently validate the full potential of our platforms, rapidly generate proof-of-concept data, and deliver innovative therapies for patients with significant unmet need.”
Third Arc Bio’s approach to I&I is anchored by its ARCTag (Tethered Agonist) Platform, which leverages multispecific antibodies to localize immune modulation directly to sites of disease. This targeted activity represents a meaningful advance beyond conventional systemic autoimmune therapies, offering the potential for enhanced efficacy and therapeutic index.
About Third Arc Bio Third Arc Bio is a clinical stage biotech company developing multifunctional antibodies that generate immune synapses to precisely activate or inhibit T cells. The lead program ARC101, is a bispecific T cell engager currently being evaluated in a Phase 1 trial for cancer patients with solid tumors expressing CLDN6. The company’s drug development engine delivers superior biologics optimized to create best-in-class T cell engagement by leveraging novel technologies that power a pipeline of high value therapeutics. The Third Arc Bio platforms include a solid tumor ARCStim Platform and an immunology & inflammation (I&I) ARCTag Platform that offers precision immune regulation to achieve superior efficacy and safety. To learn more, visit www.thirdarcbio.com.
Fuels the company’s Collaborative Intelligence™ platform growth
FORT LAUDERDALE, Fla., Feb. 4, 2026 — SynthBee, Inc., a stealth start-up pioneering its Collaborative Intelligence™ (CI™) platform, today announced the completion of $100 million in funding with Crosspoint Capital Partners, LP (Crosspoint Capital), following its initial $20 million seed funding and an additional $80 million secured last week. Crosspoint Capital is an investment firm focused on the cybersecurity, privacy, infrastructure and AI software markets.
Rony Abovitz, President & CEO, SynthBee
This investment accelerates SynthBee’s mission of building its proprietary CI™ technology platform, expansion into new markets, and continued investment in talent. SynthBee’s current and future customers span medical technology and healthcare, aerospace and defense, advanced manufacturing, automotive, financial services, and other key technology and media industries.
“At Crosspoint, we were blown away by the power of the business case for the customer. The value proposition and time-to-value cannot be ignored,” said Andre Fuetsch, Managing Director, Crosspoint Capital. “We’re incredibly excited about what the SynthBee team has created, its cohort of industry-leading customers, and the scale of the opportunity ahead. The team has invented a new way for organizations to harness intelligence at speed and with confidence. SynthBee’s differentiated CI™ platform is precisely the kind of bold, grounded innovation Crosspoint [Capital] wants to back for the long term.”
SynthBee’s mission is to help enterprises across key markets radically accelerate innovation across the product and technology lifecycles, from concept to manufacturing. The Company was founded by Rony Abovitz, the entrepreneur behind MAKO Surgical (acquired by Stryker for $1.65 billion) and Magic Leap, both recognized for redefining their categories in surgical robotics and spatial computing/XR. SynthBee’s CI™ platform aims to bring that same level of innovation and impact to a broad range of businesses in the United States and around the free world.
“SynthBee’s customers operate in mission-critical, high-performance areas across complex, regulated markets,” said Rony Abovitz, President and CEO at SynthBee. “Our proprietary CI™ platform empowers businesses to solve complex scientific, engineering, design, compliance and creative challenges at extreme speed, with high accuracy, high privacy, high reliability, under human control and with clear auditability. This investment enables us to deepen our work with businesses across numerous vertical markets that require secure, high-reliability systems for their most important engineering, manufacturing, and field operations.”
About Crosspoint Capital Crosspoint Capital is an investment firm focused on the cybersecurity, privacy, infrastructure and AI software markets. Crosspoint has assembled a group of successful operators, investors and sector experts to partner with foundational technology companies and drive differentiated returns. Crosspoint has offices in Menlo Park, CA and Boston, MA. For more information visit: www.crosspointcapital.com
About SynthBee, Inc. SynthBee, Inc. is building safe, scalable, and reliable computing intelligence to amplify and accelerate human innovation. www.synthbee.com
MAGNOLIA, Texas, Feb. 4, 2026 — Stratus® Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced a $10 million Series B financing. The financing was led by Wasatch Health Partners, a healthcare-focused investment firm pursuing growth equity and lower middle-market buyout strategies. Wasatch Health Partners invested through its Growth Fund and previously provided a $25 million convertible debt facility through its Structured Capital platform.
The proceeds from the Series B financing will be used to complete development of the Stratus Medical RF Generator and neurovasis™ basivertebral nerve ablation (BVNA) technology, expand and protect the company’s valuable patent portfolio, and fund a clinical study. These high-potential technologies will allow Stratus Medical to better serve its rapidly growing customer base while leveraging the proven and patented NIMBUS® RF Multitined Expandable Electrode (Nimbus) design.
Vertebrogenic low back pain develops when the vertebral endplates in the spine become damaged, often as a result of progressive degeneration over time. Current treatment options include medications, physical therapy, and basivertebral nerve ablation (BVNA). It is estimated that more than five million people in the United States suffer from vertebrogenic back pain.
The Stratus Medical RF Generator and neurovasis BVNA technologies are under development and have not been submitted, evaluated, or cleared by the FDA.
Luke Larsen, Vice President at Wasatch Health Partners, said, “We are pleased to expand our partnership with Stratus Medical. The company has demonstrated strong execution, consistent revenue growth, and meaningful progress across technology development and clinical initiatives. We believe the management team is well positioned to continue building on this momentum.”
Bret Boudousquie, CEO of Stratus Medical, commented, “We appreciate the long-term relationship with Wasatch Health Partners and their continued belief in our mission to help chronic pain patients by advancing RF technology. Stratus Medical is proud to work with outstanding physicians, hospitals, and ASCs, and we are anxious to deliver additional value with our future RF technologies that this financing enables us to complete.”
Doug Beall, MD, Director of Interventional Radiology, Clinical Radiology of Oklahoma, commented, “I started using Nimbus in 2020 for radiofrequency ablation pain treatments due to its larger ablation zone and ease of use. In 2022, I started providing scientific input on the neurovasis project. In 2024, my colleagues and I published the first scientific article describing the neurovasis BVNA technique utilizing CT reconstruction to assess device placement. This technology builds on the Nimbus multitined design and has the potential to offer faster, easier-to-use RF treatments and cost reductions for hospitals and ASCs.”
About Stratus Medical Stratus Medical is a medical device company focused on reducing pain and improving the quality of life for chronic pain patients through innovation. The Company has been recognized for revenue growth and innovation by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, and The Houston Business Journal. Nimbus has rapidly gained market share in the US and other countries based on ease of use, reduced procedure times, and its large-volume lesion designed to provide sustained pain relief. Stratus Medical is headquartered in Magnolia, Texas.
About Wasatch Health Partners Wasatch Health Partners is a healthcare-focused investment firm investing in medical device, life science, and outsourced medtech, and pharmaceutical services companies through growth equity, lower middle-market buyouts, and structured capital strategies. The firm is headquartered in Salt Lake City, Utah.
MIDDLETON, Wis., Feb. 3, 2026 — Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences’ reach within the US market, particularly in the MD office setting, and accelerate the development of its proprietary SAM™ Antimicrobial Technology platform to minimize wound care complications.
To learn more about Imbed Biosciences and its innovative wound care technologies, please visit www.imbedbio.com.
“The strategic investment from BioLab Holdings marks a pivotal moment for Imbed Biosciences,” said Terry Bromley, Imbed Biosciences CEO, “significantly expanding our reach of within the critical U.S. market, especially in the MD Office setting, and empowering us to further advance our technology platform, unique in its ability to integrate multiple therapeutic agents into a one-product solution to address unmet needs in wound care.”
Advancing Wound Care Solutions
This strategic investment enables Imbed Biosciences to further expand its product platform, designed to help achieve zero wound‑care complications, supported by a growing body of compelling clinical evidence. Imbed Biosciences holds a unique position in the skin substitute market, offering the only fully synthetic and antimicrobial solution of its kind. The investment from BioLab is centered around Imbed’s Microlyte® product, which is focused on chronic wound indications and engineered for effective bioburden reduction as well as cell proliferation during the crucial “scaffolding” phase of healing.
“At BioLab, we invest in platforms that have the potential to elevate how clinicians approach wound care,” said Jaime Leija, president and CEO of BioLab Holdings. “Imbed’s SAM™ technology represents a combination of scientific rigor, practical design, and long‑term scalability. We see tremendous opportunity to support its adoption in physician office settings, while helping accelerate solutions that simplify care delivery and improve outcomes for patients.”
The investment underscores a shared commitment to advancing patient outcomes in wound care through innovative, effective solutions. For details on BioLab Holdings Inc.’s announcement, refer to their press release.
About Imbed Biosciences Imbed Biosciences is a privately held medical device company advancing the next generation of wound care through its SAM™ Antimicrobial Technology. The company’s platform incorporates multiple therapeutic agents into ultra‑thin, biocompatible matrices that support skin regeneration in both chronic and acute wounds. Imbed’s expanding product portfolio is engineered to reduce infection risk, alleviate pain, and promote healing across the entire wound‑care continuum.
About BioLab Holdings, Inc. BioLab Holdings, Inc. is a Phoenix-based medical manufacturer specializing in wound protection. Its products—including Membrane Wrap – Lite ™ and Membrane Wrap ™ use human tissue allograft derived from amniotic membrane to provide structural tissue for wound protection. BioLab’s mission is optimize the standard of care through innovations grounded in science, compassion, and collaboration.
Based on the tactics of U.S. intelligence agencies, GenLogs applies AI to a nationwide sensor network, satellites, and other data streams to drive greater efficiency and defend against crimes
ARLINGTON, Va., Feb. 3, 2026 — GenLogs, whose innovative Truck Intelligence™ technology is being deployed across industries to make supply chains safer and stronger, announced it has closed $60 million in Series B funding. The round was led by Battery Ventures with participation by IVP, Cathay Innovation, and 9Yards, as well as existing investors Venrock, Steel Atlas, HOF Capital, TitletownTech, and Autotech Ventures. GenLogs previously raised $21 million in Seed and Series A funding.
Joe Sherman, chief technology officer, Ryan Joyce, chief executive officer, and Blake Balch, chief of strategy and partnerships. (Photo: GenLogs)
The company will use the new funds to continue building out its core platform—powered by its privacy-enabled network of roadside sensors—and extend capabilities to shippers, insurers, governments, and financial institutions. Current customers include Fortune 500 companies across these sectors, including logistics and supply-chain expert J.B. Hunt, trucking company Werner Enterprises, insurer AIPSO, and Jacksonville Port Authority (JAXPORT).
“The trillion-dollar trucking industry links every sector of our economy, but it is highly fragmented in its composition and still analog in its operations,” said Ryan Joyce, a veteran former CIA officer who co-founded GenLogs in 2023 and serves as CEO. “GenLogs is applying many aspects of the U.S. intelligence community’s playbook to drive total visibility in the trucking industry, resulting in more efficiency, better pricing, and protection against fraud and $35 billion in annual cargo theft.”
To do this, GenLogs leverages trillions of data points collected from millions of satellites and sensors—including cameras that sit on roadside infrastructure and ports nationwide that capture real-time data on trucks. The company then applies proprietary AI to expose patterns that enable customers to conduct better carrier sourcing, vetting, and underwriting. By understanding the true movements of a fleet, customers can verify that these patterns match the carrier’s digital footprint. This intelligence ensures that customers know the carriers they are using are real and operating on the roads with the right equipment.
GenLogs uses a three-step privacy filter to ensure that its cameras collect data only on commercial vehicles. The technology deletes any footage of private vehicles before screening for commercial markings, such as a USDOT number, and blurs the vehicle’s windows to prevent biometric person identification.
Beyond diverse commercial applications, GenLogs has worked extensively with both federal and state law enforcement over the last year to combat human trafficking, cargo theft, and narcotics smuggling. In one case, state law enforcement used GenLogs to track a truck engaged in interstate sex trafficking and ultimately recovered a female minor from the truck. In another case, a counter-narcotics agency was able to use GenLogs’ platform to uncover a drug smuggling network and ultimately raid multiple safehouses, resulting in a dozen arrests.
“In a remarkably short time, GenLogs has developed a novel data set of great commercial and prosocial value,” said Marcus Ryu, general partner at Battery Ventures, who will be joining GenLog’s board of directors. “Informed by their intelligence training, Ryan and his co-founders had the insight to recognize that the mission-critical work of multiple industries could be transformed by an incorruptible ground truth of nationwide trucking operations and freight movement.”
GenLogs is the Truck Intelligence™ platform leveraging AI on a nationwide network of roadside sensors, satellites, and proprietary datasets. GenLogs tracks all commercial vehicle patterns in the United States in order to drive better business outcomes for customers in trucking, logistics, insurance, commercial real estate, financial institutions, and governments.
OAK RIDGE, Tenn., Feb. 3, 2026 — LIS Technologies Inc.‘s (LIST) recently announced laser-based uranium enrichment facility represents a $1.38 billion investment in Oak Ridge, Tennessee, and is expected to create more than 200 jobs in the area. Through its role as Lead Project Integrator, Enveniam will coordinate and lead project management, planning, licensing, design, construction, site readiness, operations readiness and delivery for the facility — the first of its kind in the U.S. and one of the largest nuclear-related investments in Tennessee history.
Pictured (left to right): Doug Freund, BGS President/CEO and Enveniam Executive Officer; Christo Liebenberg, LIST President, Co-Founder and Chief Technical Advisor for LIS Technologies, Inc; Jay Yu, LIST Executive Chairman/CEO; Lou Qualls, BGS Senior VP/Advanced Energy Solutions Division
Alongside Tennessee Gov. Bill Lee, LIST announced its intent to develop the facility on a 206-acre site formerly known as Duct Island and now renamed “LIST Island,” located at the historic K-25 uranium enrichment plant. Enveniam, a BCP portfolio company, brings decades of experience in nuclear engineering and operations and will support LIST as it advances its patented laser isotope separation technology to meet growing demand for domestic enrichment and support U.S. energy and defense needs.
“We are proud to play a key role in this historic investment and to help bring this transformative technology to life,” said Doug Freund, President and CEO of Boston Government Services and Executive Officer of Enveniam. “This project represents a major step forward for U.S. energy independence and nuclear innovation, and we’re honored to support LIST in shaping a more secure and resilient domestic fuel cycle.”
As a trusted Lead Project Integrator for high-stakes, multidisciplinary programs, Enveniam integrates facilities, technology, suppliers and operations from concept through commissioning. Its promise is delivery certainty — cohesive, mission-ready systems that meet requirements and deliver on cost and schedule commitments.
Subject to licensing, permitting and final investment decisions, LIST intends to begin site preparation and construction in 2026, with initial commercial operations targeted before 2030. This announcement follows the company’s selection in the U.S. Department of Energy’s Low-Enriched Uranium (LEU) Enrichment Acquisition Program and further positions Oak Ridge at the forefront of nuclear energy advancement.
For more information on LIS Technologies and this announcement, visit laseristech.com. To learn more about Enveniam and its role in advancing critical energy and infrastructure initiatives, visit enveniamsolutions.com.
About Enveniam
Enveniam advances the nation’s focus on energy dominance and national security through engineering, technology and deep domain expertise. As a Lead Project Integrator, the company delivers integrated solutions across federal and energy markets, including nuclear, oil, natural gas, renewables and critical infrastructure. A BCP portfolio company, Enveniam brings the scale, agility and depth needed to address the world’s most pressing energy and security challenges. For more information, visit enveniamsolutions.com.
Investment led by Alignment Growth reinforces Kings League’s world-leading position in creator-led sports
Funding will power international growth through organic expansion and select M&A
BARCELONA, Spain and NEW YORK, Feb. 3, 2026 — Kings League, the creator-led sports competition founded by Gerard Piqué, today announced a $63 million investment round led by Alignment Growth, a U.S.-based media and entertainment investor, with participation from existing shareholders.
Kings League, the creator-led sports competition founded by Gerard Piqué, announced a $63 million investment round led by Alignment Growth, a U.S.-based media and entertainment investor.
Since its launch in Spain in 2023, Kings League has established itself as a global phenomenon in creator-led sports. The brand’s formula – seven-a-side soccer reimagined for the digital age, with teams and competitions led by superstar streamers, content creators and soccer legends including Lamine Yamal, Neymar Jr. and Kaká, and “gamified” rules that guarantee action-packed, unpredictable matches – has driven massive online engagement and redefined how younger generations engage with sport.
The investment will support Kings League’s next phase of growth, aimed at expanding the Kings League and Queens League platforms globally, including launching in the U.S. This follows Kings League’s 2025 launch of new regional leagues in Brazil, France, Germany, Italy and the MENA region, and a new national team World Cup tournament.
Over the course of 2025, Kings League generated 150 million livestreaming hours watched and more than 13 billion impressions across official social channels, consolidating its position as one of the most-watched sports properties on digital platforms globally.
Gerard Piqué, Kings League’s Founder and Chairman – now an entrepreneur following a stellar career in professional soccer with FC Barcelona, Manchester United, and Spain – said: “Kings League has become a global movement, built natively for the digital generation. Alignment Growth brings exceptional media and entertainment experience, and our partnership will help us continue to grow, bring the Kings League experience to new audiences, and explore diversification into new sports.”
Djamel Agaoua, CEO of Kings League, added: “We have proven that our model works at scale. This funding allows us to accelerate our expansion, continue innovating the format and explore strategic M&A opportunities that support our long-term vision. The ambition is clear: to build the leading global platform for creator-led sports and entertainment.”
Kevin Tsujihara, Co-Founder and Managing Partner at Alignment Growth who joined the Board of Kings League, said, “Our investment in Kings League reflects our conviction that digitally native sports properties are uniquely positioned to capture powerful, long-term growth as younger audiences shift how they discover and engage with sports. Gerard, Djamel, and the entire Kings League team have built a truly innovative and global platform combining the world’s most popular sport with a creator-aligned business model and we are thrilled to partner with them on this next phase of expansion.”
To date, Kings League has raised more than $160 million in total funding, supporting its rapid global rollout and the development of an ecosystem that now includes seven regional Kings League men’s competitions, two regional Queens League women’s competitions, and two annual World Cup tournaments, for clubs and national teams. The platform has attracted blue-chip brand partners including adidas, Fortnite, Netflix, Spotify, and Visa, as well as major broadcast and streaming partners such as DAZN and ESPN/Disney+.
About Kings League Created by football icon and entrepreneur Gerard Piqué, Kings League is a global sports-entertainment phenomenon reimagining the world’s most popular sport for the next generation. Combining elite football with the energy of the creator economy, Kings League blends fast-paced, seven-a-side action with gamified rules inspired by streaming and gaming culture—delivering a format built for modern audiences. Teams are fronted by leading streamers, content creators, and football legends, creating a unique fusion of sport, digital entertainment, and fan-focused storytelling. Since its breakout launch in Spain in 2023, Kings League has grown into a worldwide ecosystem, with competitions established across Brazil, France, Germany, Italy, MENA, Mexico, and Spain. It has expanded into the women’s game with its Queens League competitions and established two annual World Cup international tournaments, for clubs and national teams. For more information, visit https://kingsleague.pro.
About Alignment Growth Alignment Growth is a private markets specialist investor in the global Media & Entertainment industry, investing behind high-conviction themes and partnering with category-leading companies and entrepreneurs. Our team’s deep industry expertise, operator experience, and direct access to global media, entertainment, tech, and capital markets leaders enable us to identify, access, and unlock differentiated value alongside our partners. For more information, visit: www.alignmentgrowth.com.
